Hemogenyx Pharmaceuticals Plc (LON:HEMO)
London · Delayed Price · Currency is GBP · Price in GBX 451.50
-8.50 (-1.85%)
Sep 25, 2026, 10:25 AM GMT
Hemogenyx Pharmaceuticals Employees
Hemogenyx Pharmaceuticals had 16 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
16
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-610.02K GBP
Market Cap
31.28M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 16 | 0 | - |
| Dec 31, 2024 | 16 | -1 | -5.88% |
| Dec 31, 2023 | 17 | 3 | 21.43% |
| Dec 31, 2022 | 14 | 4 | 40.00% |
| Dec 31, 2021 | 10 | 2 | 25.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| IXICO | 79 |
| SkinBioTherapeutics | 41 |
| Oxford BioDynamics | 37 |
| Faron Pharmaceuticals Oy | 36 |
| Arecor Therapeutics | 33 |
| Palatin Technologies | 29 |
| Fusion Antibodies | 27 |
| Poolbeg Pharma | 15 |
Hemogenyx Pharmaceuticals News
- 22 days ago - Hemogenyx Pharmaceuticals PLC Announces Exercise of Warrants and Issue of Equity - Accesswire
- 6 weeks ago - Hemogenyx Pharmaceuticals PLC Announces Collaboration with Cellin Technologies - Accesswire
- 1 month ago - Hemogenyx Pharmaceuticals PLC Announces Collaboration and Company Update - Accesswire
- 3 months ago - Hemogenyx Pharmaceuticals PLC Announces Notice of AGM - Accesswire
- 3 months ago - Hemogenyx Pharmaceuticals PLC Announces Grant of Options and Extension of Warrant Term - Accesswire
- 4 months ago - Hemogenyx Pharmaceuticals PLC Announces Final Results - Accesswire
- 5 months ago - Hemogenyx Pharmaceuticals PLC Announces Institutional Fundraise - Accesswire
- 5 months ago - Hemogenyx Pharmaceuticals PLC Announces Annual IND Report with FDA - Accesswire